|
rs11881222
|
|
Hepatitis C
|
|
0.060 |
GeneticVariation
|
BEFREE |
Multivariate logistic regression of the three markers showed that the A/A genotypes in both rs11506105 (EFGR) and rs11881222 (IL28B), and the C/C genotype in rs12979860 (IL28B) are associated with HCV clearance (recessive model: odds ratio (OR)=2.06, 95% confidence interval (95% CI)=1.09-3.88, P=0.025; OR=2.09, 95% CI=1.23-3.60, P=0.007; and OR=1.95, 95% CI=1.15-3.35, P=0.014 for rs11506105, rs12979860 and rs11881222, respectively).
|
26378651 |
2015 |
|
rs11881222
|
|
Hepatitis C
|
|
0.060 |
GeneticVariation
|
BEFREE |
This study demonstrated that Indonesian patients with chronic hepatitis C (mostly ethnic Java people) mostly were infected with hepatitis C virus (HCV) genotype 1; however, they carried mainly the major genotypes of interleukin 28B (IL-28B) single nucleotide polymorphisms (SNPs) (rs12979860 CC, rs11881222 TT, rs8103142 AA, and rs8099917 TT), and they mostly achieved sustained virological responses to pegylated interferon/ribavirin treatment.
|
24696021 |
2014 |
|
rs11881222
|
|
Hepatitis C
|
|
0.060 |
GeneticVariation
|
BEFREE |
Haplotype analysis showed that IL28B (rs12980275, rs11881222, rs12979860 and rs8099917) haplotype AACT had a protective effect for HCV infection (OR = 0.52, 95% CI = 0.33-0.83, P = 0.00551).
|
24144988 |
2014 |
|
rs11881222
|
|
Hepatitis C
|
|
0.060 |
GeneticVariation
|
BEFREE |
To estimate the impact of interleukin 28B (IL28B) polymorphisms (rs12980275, rs8099917, rs7248668, and rs11881222) and their haplotypes on hepatitis C virus (HCV) treatment (peg-interferon-α and ribavirin) success in 324 HIV/HCV-coinfected patients.
|
23135173 |
2013 |
|
rs11881222
|
|
Hepatitis C
|
|
0.060 |
GeneticVariation
|
BEFREE |
The major alleles of IL28B (rs12980275 A, rs11881222 A, rs8099917 T, and rs7248668 G) are associated with increased odds of liver disease severity in HIV patients infected with HCV-genotype 3.
|
23103287 |
2013 |
|
rs11881222
|
|
Hepatitis C
|
|
0.060 |
GeneticVariation
|
BEFREE |
The exonic rs8103142 CT, the promoter rs12979860 CT and the intronic rs11881222 AG genotypes were associated with a decreased HCV clearance rate with adjusted odds ratios (aOR) of 0.3 (95% CI, 0.1-0.7), 0.4 (95% CI, 0.2-0.8) and 0.4 (95% CI, 0.2-0.8), respectively.
|
21070502 |
2011 |
|
rs8103142
|
|
Hepatitis C
|
|
0.050 |
GeneticVariation
|
BEFREE |
We tested the association of spontaneous clearance and three single nucleotide polymorphisms (SNPs) near the Interferon-lambda 3 (IFNL3) gene (rs12979860, rs8099917, functional variant rs8103142) and compared the SNP frequencies between HIV-HCV co-infected whites and Aboriginals from the Canadian Co-infection Cohort.
|
25803108 |
2015 |
|
rs8103142
|
|
Hepatitis C
|
|
0.050 |
GeneticVariation
|
BEFREE |
This study demonstrated that Indonesian patients with chronic hepatitis C (mostly ethnic Java people) mostly were infected with hepatitis C virus (HCV) genotype 1; however, they carried mainly the major genotypes of interleukin 28B (IL-28B) single nucleotide polymorphisms (SNPs) (rs12979860 CC, rs11881222 TT, rs8103142 AA, and rs8099917 TT), and they mostly achieved sustained virological responses to pegylated interferon/ribavirin treatment.
|
24696021 |
2014 |
|
rs8103142
|
|
Hepatitis C
|
|
0.050 |
GeneticVariation
|
BEFREE |
Our aim was to establish an association between three IL28B SNPs (rs8099917, rs12979860, and rs8103142) and the peg-IFNα/RBV treatment response in a Mexican population cohort with chronic HCV.
|
23109451 |
2013 |
|
rs8103142
|
|
Hepatitis C
|
|
0.050 |
GeneticVariation
|
BEFREE |
We examined whether the combined determination of the IL28B single-nucleotide polymorphisms (SNPs), rs12979860, rs8099917, rs12980275, and rs8103142, might improve the prediction of SVR in patients with HCV.
|
22234924 |
2012 |
|
rs8103142
|
|
Hepatitis C
|
|
0.050 |
GeneticVariation
|
BEFREE |
Further, we found significant differences in HCV RNA levels among individuals chronically infected with HCV genotype 1 for rs8103142 and rs12979860 (P ≤ 0.05).
|
21070502 |
2011 |
|
rs4803217
|
|
Hepatitis C
|
|
0.040 |
GeneticVariation
|
BEFREE |
The rs4803217 SNP is a strong, independent and superior predictor of SVR and relapse in HCV genotype 1 infected CHC patients treated with PEG-IFN-α and RBV.
|
28638221 |
2017 |
|
rs4803217
|
|
Hepatitis C
|
|
0.040 |
GeneticVariation
|
BEFREE |
Among AA participants, associations were stronger for IFNL4-ΔG/TT than rs4803217 for undetectable HCV RNA at week 24 in Virahep-C (p=0.03) and week 20 in HALT-C (p=0.03), as well as for spontaneous HCV clearance (p=0.048).
|
26186989 |
2015 |
|
rs4803217
|
|
Hepatitis C
|
|
0.040 |
GeneticVariation
|
BEFREE |
We analyzed a variant (rs4803217 G/T) located within the IFNL3 mRNA 3' untranslated region (UTR); the G allele (protective allele) is associated with elevated therapeutic HCV clearance.
|
26531896 |
2015 |
|
rs4803217
|
|
Hepatitis C
|
|
0.040 |
GeneticVariation
|
BEFREE |
This analysis included the two strongest tag predictors for HCV clearance, rs8099917 and rs12979860, and four causal variants (rs4803219, rs28416813, rs8103142, and rs4803217) located in the IL28B promoter, coding, and 3'-untranslated regions.
|
22328925 |
2012 |
|
rs142346548
|
|
Hepatitis C
|
|
0.030 |
GeneticVariation
|
BEFREE |
Significant modulation of IFN-λ4 activity by a genetic variant (P70S) supports IFN-λ4, and not other type III IFNs encoded in the same genomic locus, as the primary functional cause of the association with HCV clearance.
|
31241411 |
2019 |
|
rs142346548
|
|
Hepatitis C
|
|
0.030 |
GeneticVariation
|
BEFREE |
The recently described rs368234815 TT/ΔG dinucleotide and rs117648444 nonsynonymous P70S polymorphisms in IFN lambda 4 (IFNL4) gene, which are strongly associated with response to IFN in hepatitis C virus (HCV) infection, could be also useful in IFN-treated CHB patients.
|
28732143 |
2018 |
|
rs142346548
|
|
Hepatitis C
|
|
0.030 |
GeneticVariation
|
BEFREE |
Confounding by Single Nucleotide Polymorphism rs117648444 (P70S) Affects the Association of Interferon Lambda Locus Variants with Response to Interferon-α-Ribavirin Therapy in Patients with Chronic Genotype 3 Hepatitis C Virus Infection.
|
28727946 |
2017 |
|
rs62120527
|
|
Hepatitis C
|
|
0.010 |
GeneticVariation
|
BEFREE |
K154E greatly enhanced in vitro activity in a range of antiviral (HCV, Zika virus, influenza virus and encephalomyocarditis virus) and gene expression assays.
|
30308076 |
2018 |